Biotech Values

[DewDiligence]

isolution: What is your opinion of the InnoRx device? T.i.a.

I just finished listening to the SRDX-InnoRx CC and I think this platform is a nice fit for SRDX’s expertise in polymers. In theory, virtually any AMD drug can be formulated with SRDX’s polymers for slow-release delivery over a period as long as two years. That sure beats having to get 15-20 intravitreal injections over the same time period.

Moreover, a significant drawback of AMD/DME drugs that require regular retreatment is patient non-compliance: if a patient misses even one treatment, the course of the disease might be irrevocably affected. The InnoRx device does not have this problem.